Sio Gene Therapies Inc
F:6YY

Watchlist Manager
Sio Gene Therapies Inc Logo
Sio Gene Therapies Inc
F:6YY
Watchlist
Price: 0.3265 EUR Market Closed
Market Cap: 24.2m EUR

Sio Gene Therapies Inc
Tax Provision

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Sio Gene Therapies Inc
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Sio Gene Therapies Inc
F:6YY
Tax Provision
-$290k
CAGR 3-Years
-61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Tax Provision
$735m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Tax Provision
-$1.8B
CAGR 3-Years
-13%
CAGR 5-Years
-28%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Tax Provision
-$1.2B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Tax Provision
-$773.6m
CAGR 3-Years
-1%
CAGR 5-Years
-29%
CAGR 10-Years
-37%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Tax Provision
-$522.6m
CAGR 3-Years
8%
CAGR 5-Years
-10%
CAGR 10-Years
2%
No Stocks Found

Sio Gene Therapies Inc
Glance View

Market Cap
24.2m EUR
Industry
Biotechnology

Sio Gene Therapies Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company is headquartered in New York City, New York and currently employs 42 full-time employees. The company went IPO on 2015-06-11. The firm is focused on developing gene therapies for neurodegenerative diseases. The firm is developing a pipeline of product candidates for the treatment of these debilitating diseases, including GM1 gangliosidosis, GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, and Parkinson's disease. The firm is under three clinical-stage programs, AXO-AAV-GM1, AXO-AAV-GM2 and AXO-Lenti-PD. The AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene. The AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases. The AXO-AAV-GM2 program utilizes dual AAV vectors to deliver functional copies of both the HEXA gene and the HEXB gene. The AXO-Lenti-PD program for the treatment of Parkinson's disease, comprised of the ProSavin Phase 0.5 study.

6YY Intrinsic Value
Not Available

See Also

What is Sio Gene Therapies Inc's Tax Provision?
Tax Provision
-290k USD

Based on the financial report for Dec 31, 2022, Sio Gene Therapies Inc's Tax Provision amounts to -290k USD.

What is Sio Gene Therapies Inc's Tax Provision growth rate?
Tax Provision CAGR 3Y
-61%

Over the last year, the Tax Provision growth was -383%. The average annual Tax Provision growth rates for Sio Gene Therapies Inc have been -61% over the past three years .

Back to Top